Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.32 |
| ▸ | CD99 | P14209 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837928 | 0.88 | CYP1A2 (0.43) | IMPDH2IMPDH1ADORA2AADORA2BADORA3 | |
| SCHEMBL22837883 | 0.88 | ADORA3 (0.37) | ADORA2AADORA3 | |
| SCHEMBL22837894 | 0.82 | ADORA2A (0.36) | CHKAADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22837934 | 0.81 | PDE4A (0.37) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22837902 | 0.81 | NPEPPS (0.33) | — | |
| SCHEMBL20711282 | 0.80 | IMPDH2 (0.53) | IMPDH2IMPDH1ADORA2AADORA2BADORA3 | |
| SCHEMBL22837920 | 0.78 | ADORA3 (0.35) | ADORA2AADORA3 | |
| SCHEMBL22837900 | 0.77 | ADORA3 (0.36) | ADORA2AADORA3 | |
| SCHEMBL22837895 | 0.74 | PI4KA (0.34) | ADORA2AADORA3 | |
| SCHEMBL21710848 | 0.68 | ADORA2A (0.58) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | IMPDH2 150/4885IMPDH1 69/4885CHKA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.